Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of erenumab on CGRP- and cilostazol-induced migraine-like attacks
2020-000661-16Phase 4Completed
- Sponsor
- Rigshospitalet Glostrup
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of erenumab in migraine and migraine without aura, sponsored by Rigshospitalet Glostrup. Primary endpoint: Incidence of migraine-like attacks. Started Mar 2020; status: completed.
02
Drugs
erenumab
03
Conditions
migrainemigraine without aura
Beyond the preview
Go deeper on 2020-000661-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000661-16.